logo

Chemocentryx Inc. (CCXI)



Trade CCXI now with
  Date
  Headline
5/23/2017 8:35:43 AM ChemoCentryx Granted EU Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3G
3/22/2017 8:33:11 AM ChemoCentryx Gets FDA Orphan Drug Designation For Avacopan In Treatment Of Debilitating Kidney Disease C3G
3/14/2017 4:09:54 PM ChemoCentryx Q4 Loss/share $0.16 Vs. Loss $0.26 Year Ago
11/7/2016 8:37:04 AM ChemoCentryx Reports Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials Of Avacopan
10/20/2016 8:33:48 AM ChemoCentryx Adds Henry McKinnell To Board Of Directors
10/17/2016 8:36:05 AM ChemoCentryx Announces Presentation Of Positive Data From Pilot Phase II Trial Of CCX168 In AHUS
6/16/2016 8:33:09 AM ChemoCentryx Announces Positive Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study
5/23/2016 9:20:06 AM ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial
5/10/2016 7:26:07 AM ChemoCentryx Q1 Net Loss $15.2 Mln Or $0.34/shr Vs Loss $12.0 Mln Or $0.28/shr Last Year
4/28/2016 8:36:50 AM ChemoCentryx Gets FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168
4/18/2016 8:36:48 AM ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research
1/6/2016 7:11:42 AM ChemoCentryx Announces Positive Top-line Data From Its’ Phase II CLEAR Trial With CCX168 In Patients With AAV
8/6/2015 5:55:15 PM ChemoCentryx Q2 Loss/share $0.28, Same As Last Year
7/30/2015 8:38:28 AM ChemoCentryx Appoints Thomas Edwards To Board
5/6/2015 5:28:39 PM ChemoCentryx Posts Q1 Loss Per Share Of $0.28 Vs. Loss $0.27 Year Ago
  
 
>